An observational study in Schizophrenia Disorder, Frontotemporal Dementia, Behavioral Variant and Major Depressive Disorder (MDD), sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau. Enrolling by invitation at 1 site in Spain. Open to participants aged 40 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-11.
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 156 studies in Schizophrenia with a site in Spain — 12 open to participants now, 14 under way, 2 of them phase 3. Schizophrenia · Spain.
Among the 156 studies in Schizophrenia with a site in Spain, this one is the 19th largest by planned enrollment of the 32 observational ones that give a count, is one of 2 that started in 2025, is one of 32 observational ones, reaches primary completion later than 11 of the 13 other live ones, and was the 147th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →12 of the 156 studies in Schizophrenia with a site in Spain are open now. Recruiting first, the newest first:
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Spain, United States, Argentina and 4 more countries
Ages 18–65
University of the Basque Country (UPV/EHU) · Sites in Spain
Ages 18–65
Karuna Therapeutics, Inc., a Bristol Myers Squibb company · Sites in Spain, United States, Australia and 8 more countries
Ages 5–17
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · Sites in Spain
Ages 18+
Dr. Inge Winter · Sites in Spain, Austria, Germany and 2 more countries
Ages 18–70
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 40 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
156 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 39 · Phase 4 20
First in 2001; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 150 is below the median of 178 across 508 observational studies indexed under Schizophrenia.
Median enrollment 200 across the 123 interventional studies, 200 across the 32 observational. Of the 121 that completed or were terminated, 36 (30%) have results posted.
This tab as a report to print or save as PDF → With an account.
81 of 156 have an industry lead sponsor. The 10 most frequent:
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau is the lead sponsor of 343 studies on the registry; 65 are open to participants now.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau has 5 studies filed under Schizophrenia — fewer than ten, so there is no comparison to draw.
1 of the studies in Schizophrenia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07921667International University of La RiojaSleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment | 2027-08 |
Add it to your calendar (.ics) → With an account.
Among the 156 studies in Schizophrenia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Clinical Study A. Retrospective Neuropathological Study of Synapse dysfunction.
This is a cross-sectional study of patients retrospectively collected from existing postmortem collections and from existing collections of iPSC-derived neurons. Postmortem tissue and iPSC-derived neurons from age and sex-matched unaffected volunteers without a MD or ND diagnosis are used as controls.
This study will:
Resource 1. Frozen samples and paraffin sections from necropsy tissue will be provided by the University of Basque Country, Bilbao. Autopsies are performed in the Basque Institute of Legal Medicine, Bilbao, Spain.
Resource 2. Frozen samples and paraffin sections from necropsy tissue are recruited from the neurological tissue bank collection (IDIBAPS, Barcelona).
Resource 3. A collection of human induced pluripotent stem cell clones from clinically and genetically well-phenotyped schizophrenia (Natural and Medical Sciences Institute), behavioural variant frontotemporal dementia patients (University of Eastern Finland) and unaffected controls (both sites) that have already been functionally characterised in previous studies.
Inclusion criteria for psychiatric disorders:
Exclusion criteria for psychiatric disorders:
For schizophrenia, cases displaying additional neurological or psychiatric conditions, such as histories of substance use disorder will be excluded. Postmortem delay >24h (to minimise perimortem confounding variables potentially affecting tissue quality.
Inclusion criteria for Neurodegenerative diseases:
Exclusion criteria for Neurodegenerative diseases:
Postmortem delay >24h (to minimise perimortem confounding variables potentially affecting tissue quality.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cases that arrive to autopsy with a previous clinical diagnosis of major depressive disorder
Cases that arrive to autopsy with a previous clinical diagnosis of schizophrenia or iPSC clones derived from a patient with a previous clinical diagnosis of schizophrenia
Cases that arrive to autopsy with a previous clinical diagnosis of major depressive disorder
Cases that arrived to autopsy without a prior diagnosis of a neurodegenerative or psychiatric condition or iPSC clones derived from a cognitively unimpaired healthy volunteer
Cases that arrive to autopsy with neuropathological confirmation of Alzheimer's disease
Cases that arrive to autopsy with neuropathological confirmation of frontotemporal lobar degeneration
Synaptic gene dysregulation in schizophrenia and frontotemporal dementia
A list of genes that are differentially expressed in schizophrenia and frontotemporal dementia compared to controls identified by RNA sequencing a) synaptic fractions isolated from postmortem tissue from the prefrontal cortex of autopsy cases with a clinical diagnosis of schizophrenia or confirmation of frontotemporal lobar degeneration and b) established iPSC clones from patients with a clinical diagnosis of schizophrenia or behavioural variant frontotemporal dementia.
Time frame: January 2025 to December 2029
Molecular pathways related to synapse dysfunction in major depressive disorder, bipolar disorder and schizophrenia
A list of biological processes that are enriched for proteins that are differentially expressed in major depressive disorder, bipolar disorder and schizophrenia compared to controls identified by proteomic analysis of synaptic fractions isolated from postmortem tissue from the prefrontal cortex of autopsy cases with a clinical diagnosis ofmajor depressive disorder, bipolar disorder or schizophrenia
Time frame: January 2025 to December 2029
Impact of psychiatric and neurodegenerative disorders on synapse density in affected brain regions.
Density of immunoreactive objects labelled with an antibody to pre and post synapse markers (vGlut1, PSD-95) in the prefrontal cortex, hippocampus and striatum from autopsy cases with a prior diagnosis of major depressive disorder, bipolar disorder, schizophrenia and unaffected controls and brain donors with neuropathological confirmation of Alzheimer's disease or frontotemporal dementia and unaffected controls.
Time frame: January 2028 to December 2029
Effects of psychotropic drugs on molecular pathways at the synapse related to major depressive disorder, schizophrenia and bipolar disorder
A list of proteins that correlate with the concentrations of \>200 psychoactive drugs and metabolites in both blood and cerebellum from autopsy cases with a prior diagnosis of major depressive disorder, schizophrenia or bipolar disorder
Time frame: July 2025 to December 2027
Plan to share: Yes — Pseudoanonymised age, biological sex, ethnicity, country of origin/residence, diagnosis, age-at-death, postmortem interval, suicide attempts, comorbidities, therapies, toxicology, synapse density, transcriptome, proteome will uploaded to Zenodo (or ProteomeXchange Consortium PRIDE repository for genomic and proteomic data), which use DOIs as persistent and unique identifiers
Supporting information: Study protocol, Statistical analysis plan, Clinical study report, Analytic code
Time frame: Jan2025-Jan2035
Access criteria: clinical and research communities
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Jun 2029, 52 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau →